{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:06:30Z","timestamp":1793995590132,"version":"4.8.0"},"reference-count":190,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["No.2022YFA1305600"],"award-info":[{"award-number":["No.2022YFA1305600"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.82470584"],"award-info":[{"award-number":["No.82470584"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Biofilms Microbiomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic liver disease (CLD) causes 2 million annual deaths (4% of all global deaths). While gut bacteria are widely studied, intestinal fungi remain largely overlooked despite their critical roles in maintaining microecological homeostasis. This review summarizes fungal characteristics in alcohol-related liver disease, metabolic dysfunction-associated steatotic liver disease, primary sclerosing cholangitis, and cirrhosis, analyzing roles of fungi and their metabolites. Targeting the gut fungal community may offer therapeutic strategies for CLD.<\/jats:p>","DOI":"10.1038\/s41522-026-00961-5","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:26:55Z","timestamp":1773156415000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The role and possible mechanism of intestinal fungi in the progression of chronic liver diseases"],"prefix":"10.1038","volume":"12","author":[{"given":"Yirui","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huikuan","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"961_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","volume":"70","author":"SK Asrani","year":"2019","unstructured":"Asrani, S. K., Devarbhavi, H., Eaton, J. & Kamath, P. S. Burden of liver diseases in the world. J. Hepatol. 70, 151\u2013171 (2019).","journal-title":"J. Hepatol."},{"key":"961_CR2","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3350\/cmh.2025.0043","volume":"31","author":"S Shiina","year":"2025","unstructured":"Shiina, S. et al. Liver disease trends in the Asia-Pacific region for the next 50 years. Clin. Mol. Hepatol. 31, 671\u2013684 (2025).","journal-title":"Clin. Mol. Hepatol."},{"key":"961_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41392-024-02072-z","volume":"10","author":"C Gan","year":"2025","unstructured":"Gan, C. et al. Liver diseases: Epidemiology, causes, trends and predictions. Sig Transduct. Target Ther. 10, 33 (2025).","journal-title":"Sig Transduct. Target Ther."},{"key":"961_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70155","volume":"45","author":"Y Zhao","year":"2025","unstructured":"Zhao, Y. et al. Global burden of chronic liver disease and temporal trends: A population-based analysis from 1990 to 2021 with projections to 2050. Liver Int. 45, e70155 (2025).","journal-title":"Liver Int."},{"key":"961_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41423-020-00592-6","volume":"18","author":"R Wang","year":"2021","unstructured":"Wang, R. et al. Gut microbiome, liver immunology, and liver diseases. Cell Mol. Immunol. 18, 4\u201317 (2021).","journal-title":"Cell Mol. Immunol."},{"key":"961_CR6","doi-asserted-by":"publisher","first-page":"923599","DOI":"10.3389\/fimmu.2022.923599","volume":"13","author":"L Wang","year":"2022","unstructured":"Wang, L., Cao, Z., Zhang, L., Li, J. & Lv, W. The role of gut microbiota in some liver diseases: From an immunological perspective. Front Immunol. 13, 923599 (2022).","journal-title":"Front Immunol."},{"key":"961_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nature08821","volume":"464","author":"J Qin","year":"2010","unstructured":"Qin, J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59\u201365 (2010).","journal-title":"Nature"},{"key":"961_CR8","first-page":"1285","volume":"30","author":"LL Zhang","year":"2022","unstructured":"Zhang, L. L., Deng, W. H. & Wang, W. X. Characteristics and research progress on the role of intestinal fungi in chronic liver disease]. Zhonghua Gan Zang Bing. Za Zhi 30, 1285\u20131288 (2022).","journal-title":"Zhonghua Gan Zang Bing. Za Zhi"},{"key":"961_CR9","doi-asserted-by":"publisher","first-page":"001631","DOI":"10.1099\/mic.0.001631","volume":"171","author":"R Mohammadi","year":"2025","unstructured":"Mohammadi, R., Morovati, H. & Safari, F. The human mycobiome: a critical yet understudied component of health and disease. Microbiology 171, 001631 (2025).","journal-title":"Microbiology"},{"key":"961_CR10","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/liv.15160","volume":"42","author":"S Zeng","year":"2022","unstructured":"Zeng, S. & Schnabl, B. Roles for the mycobiome in liver disease. Liver Int 42, 729\u2013741 (2022).","journal-title":"Liver Int"},{"key":"961_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1126\/science.aaz8086","volume":"368","author":"HH Kong","year":"2020","unstructured":"Kong, H. H. & Segre, J. A. Cultivating fungal research. Science 368, 365\u2013366 (2020).","journal-title":"Science"},{"key":"961_CR12","doi-asserted-by":"publisher","first-page":"e1012377","DOI":"10.1371\/journal.ppat.1012377","volume":"20","author":"S Zeng","year":"2024","unstructured":"Zeng, S. & Schnabl, B. Gut mycobiome alterations and implications for liver diseases. PLoS Pathog. 20, e1012377 (2024).","journal-title":"PLoS Pathog."},{"key":"961_CR13","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.jhep.2022.12.006","volume":"78","author":"P Hartmann","year":"2023","unstructured":"Hartmann, P. & Schnabl, B. Fungal infections and the fungal microbiome in hepatobiliary disorders. J. Hepatol. 78, 836\u2013851 (2023).","journal-title":"J. Hepatol."},{"key":"961_CR14","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/hep.30832","volume":"71","author":"S Lang","year":"2020","unstructured":"Lang, S. et al. Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis. Hepatology 71, 522\u2013538 (2020).","journal-title":"Hepatology"},{"key":"961_CR15","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.jhep.2021.11.029","volume":"76","author":"M Demir","year":"2022","unstructured":"Demir, M. et al. The fecal mycobiome in non-alcoholic fatty liver disease. J. Hepatol. 76, 788\u2013799 (2022).","journal-title":"J. Hepatol."},{"key":"961_CR16","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1172\/JCI90562","volume":"127","author":"A-M Yang","year":"2017","unstructured":"Yang, A.-M. et al. Intestinal fungi contribute to development of alcoholic liver disease. J. Clin. Invest 127, 2829\u20132841 (2017).","journal-title":"J. Clin. Invest"},{"key":"961_CR17","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jhep.2019.09.029","volume":"72","author":"H Chu","year":"2020","unstructured":"Chu, H. et al. The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease. J. Hepatol. 72, 391\u2013400 (2020).","journal-title":"J. Hepatol."},{"key":"961_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.semcdb.2018.03.003","volume":"89","author":"EC Patin","year":"2019","unstructured":"Patin, E. C., Thompson, A. & Orr, S. J. Pattern recognition receptors in fungal immunity. Semin Cell Dev. Biol. 89, 24\u201333 (2019).","journal-title":"Semin Cell Dev. Biol."},{"key":"961_CR19","doi-asserted-by":"publisher","first-page":"e0051623","DOI":"10.1128\/iai.00516-23","volume":"92","author":"O Jensen","year":"2024","unstructured":"Jensen, O., Trujillo, E., Hanson, L. & Ost, K. S. Controlling Candida: immune regulation of commensal fungi in the gut. Infect. Immun. 92, e0051623 (2024).","journal-title":"Infect. Immun."},{"key":"961_CR20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.5009\/gnl18579","volume":"14","author":"N You","year":"2020","unstructured":"You, N., Zhuo, L., Zhou, J., Song, Y. & Shi, J. The role of intestinal fungi and its metabolites in chronic liver diseases. Gut Liver 14, 291\u2013296 (2020).","journal-title":"Gut Liver"},{"key":"961_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-017-0373-4","volume":"5","author":"AK Nash","year":"2017","unstructured":"Nash, A. K. et al. The gut mycobiome of the human microbiome project healthy cohort. Microbiome 5, 153 (2017).","journal-title":"Microbiome"},{"key":"961_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.funeco.2015.01.006","volume":"15","author":"HE Hallen-Adams","year":"2015","unstructured":"Hallen-Adams, H. E., Kachman, S. D., Kim, J., Legge, R. M. & Mart\u00ednez, I. Fungi inhabiting the healthy human gastrointestinal tract: A diverse and dynamic community. Fungal Ecol. 15, 9\u201317 (2015).","journal-title":"Fungal Ecol."},{"key":"961_CR23","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41579-023-00904-3","volume":"21","author":"CL Hsu","year":"2023","unstructured":"Hsu, C. L. & Schnabl, B. The gut-liver axis and gut microbiota in health and liver disease. Nat. Rev. Microbiol 21, 719\u2013733 (2023).","journal-title":"Nat. Rev. Microbiol"},{"key":"961_CR24","first-page":"710","volume":"15","author":"X Deng","year":"2025","unstructured":"Deng, X. et al. Composition, influencing factors, and effects on host nutrient metabolism of fungi in gastrointestinal tract of monogastric animals. Anim. (Basel) 15, 710 (2025).","journal-title":"Anim. (Basel)"},{"key":"961_CR25","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrgastro.2012.156","volume":"9","author":"HJ Flint","year":"2012","unstructured":"Flint, H. J., Scott, K. P., Louis, P. & Duncan, S. H. The role of the gut microbiota in nutrition and health. Nat. Rev. Gastroenterol. Hepatol. 9, 577\u2013589 (2012).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"961_CR26","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.cell.2022.01.017","volume":"185","author":"I Leonardi","year":"2022","unstructured":"Leonardi, I. et al. Mucosal fungi promote gut barrier function and social behavior via Type 17 immunity. Cell 185, 831\u2013846.e14 (2022).","journal-title":"Cell"},{"key":"961_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/srep45840","volume":"8","author":"D Li","year":"2017","unstructured":"Li, D. et al. Microbial biogeography and core microbiota of the rat digestive tract. Sci. Rep. 8, 45840 (2017).","journal-title":"Sci. Rep."},{"key":"961_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/gm467","volume":"5","author":"L Cui","year":"2013","unstructured":"Cui, L., Morris, A. & Ghedin, E. The human mycobiome in health and disease. Genome Med 5, 63 (2013).","journal-title":"Genome Med"},{"key":"961_CR29","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1053\/j.gastro.2020.09.014","volume":"160","author":"Y Sun","year":"2021","unstructured":"Sun, Y. et al. Population-level configurations of gut mycobiome across 6 ethnicities in urban and rural China. Gastroenterology 160, 272\u2013286.e11 (2021).","journal-title":"Gastroenterology"},{"key":"961_CR30","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2025.2487209","volume":"17","author":"L Buttler","year":"2025","unstructured":"Buttler, L. et al. Distinct clusters of bacterial and fungal microbiota in end-stage liver cirrhosis correlate with antibiotic treatment, intestinal barrier impairment, and systemic inflammation. Gut Microbes 17, 2487209 (2025).","journal-title":"Gut Microbes"},{"key":"961_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01443-2","volume":"11","author":"Y Guo","year":"2021","unstructured":"Guo, Y. et al. A diet high in sugar and fat influences neurotransmitter metabolism and then affects brain function by altering the gut microbiota. Transl. Psychiatry 11, 328 (2021).","journal-title":"Transl. Psychiatry"},{"key":"961_CR32","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1053\/j.gastro.2020.04.077","volume":"159","author":"DM Chopyk","year":"2020","unstructured":"Chopyk, D. M. & Grakoui, A. Contribution of the intestinal microbiome and gut barrier to hepatic disorders. Gastroenterology 159, 849\u2013863 (2020).","journal-title":"Gastroenterology"},{"key":"961_CR33","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41575-018-0011-z","volume":"15","author":"A Tripathi","year":"2018","unstructured":"Tripathi, A. et al. The gut-liver axis and the intersection with the microbiome. Nat. Rev. Gastroenterol. Hepatol. 15, 397\u2013411 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"961_CR34","doi-asserted-by":"publisher","first-page":"775526","DOI":"10.3389\/fimmu.2021.775526","volume":"12","author":"Z Zheng","year":"2021","unstructured":"Zheng, Z. & Wang, B. The gut-liver axis in health and disease: The role of gut microbiota-derived signals in liver injury and regeneration. Front Immunol. 12, 775526 (2021).","journal-title":"Front Immunol."},{"key":"961_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00535-020-01740-5","volume":"56","author":"L Jiang","year":"2021","unstructured":"Jiang, L. et al. The gut mycobiome: a novel player in chronic liver diseases. J. Gastroenterol. 56, 1\u201311 (2021).","journal-title":"J. Gastroenterol."},{"key":"961_CR36","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.3390\/ijms20184568","volume":"20","author":"M Meroni","year":"2019","unstructured":"Meroni, M., Longo, M. & Dongiovanni, P. Alcohol or gut microbiota: Who is the guilty? Int J. Mol. Sci. 20, 4568 (2019).","journal-title":"Int J. Mol. Sci."},{"key":"961_CR37","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1002\/hep.31583","volume":"73","author":"SK Asrani","year":"2021","unstructured":"Asrani, S. K., Mellinger, J., Arab, J. P. & Shah, V. H. Reducing the global burden of alcohol-associated liver disease: A blueprint for action. Hepatology 73, 2039\u20132050 (2021).","journal-title":"Hepatology"},{"key":"961_CR38","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/hep.30866","volume":"71","author":"DW Crabb","year":"2020","unstructured":"Crabb, D. W., Im, G. Y., Szabo, G., Mellinger, J. L. & Lucey, M. R. Diagnosis and treatment of alcohol-associated liver diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology 71, 306\u2013333 (2020).","journal-title":"Hepatology"},{"key":"961_CR39","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMra2207599","volume":"387","author":"R Bataller","year":"2022","unstructured":"Bataller, R., Arab, J. P. & Shah, V. H. Alcohol-associated hepatitis. N. Engl. J. Med 387, 2436\u20132448 (2022).","journal-title":"N. Engl. J. Med"},{"key":"961_CR40","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.3390\/ijms24043735","volume":"24","author":"M Duki\u0107","year":"2023","unstructured":"Duki\u0107, M. et al. Alcohol, inflammation, and microbiota in alcoholic liver disease. Int J. Mol. Sci. 24, 3735 (2023).","journal-title":"Int J. Mol. Sci."},{"key":"961_CR41","doi-asserted-by":"publisher","first-page":"E4485","DOI":"10.1073\/pnas.1415174111","volume":"111","author":"S Leclercq","year":"2014","unstructured":"Leclercq, S. et al. Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. Proc. Natl. Acad. Sci. USA 111, E4485\u2013E4493 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"961_CR42","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jhep.2018.10.023","volume":"70","author":"B Gao","year":"2019","unstructured":"Gao, B., Ahmad, M. F., Nagy, L. E. & Tsukamoto, H. Inflammatory pathways in alcoholic steatohepatitis. J. Hepatol. 70, 249\u2013259 (2019).","journal-title":"J. Hepatol."},{"key":"961_CR43","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.chom.2023.02.001","volume":"31","author":"S Zeng","year":"2023","unstructured":"Zeng, S. et al. Candida albicans-specific Th17 cell-mediated response contributes to alcohol-associated liver disease. Cell Host Microbe 31, 389\u2013404.e7 (2023).","journal-title":"Cell Host Microbe"},{"key":"961_CR44","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s41586-019-1742-x","volume":"575","author":"Y Duan","year":"2019","unstructured":"Duan, Y. et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature 575, 505\u2013511 (2019).","journal-title":"Nature"},{"key":"961_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.699253","volume":"12","author":"P Hartmann","year":"2021","unstructured":"Hartmann, P. et al. Dynamic changes of the fungal microbiome in alcohol use disorder. Front Physiol. 12, 699253 (2021).","journal-title":"Front Physiol."},{"key":"961_CR46","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","volume":"29","author":"ML Teng","year":"2023","unstructured":"Teng, M. L. et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 29, S32\u2013S42 (2023).","journal-title":"Clin. Mol. Hepatol."},{"key":"961_CR47","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi, K. et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 7, 851\u2013861 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"961_CR48","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/hep.31150","volume":"71","author":"J Zhou","year":"2020","unstructured":"Zhou, J. et al. Epidemiological Features of NAFLD From 1999 to 2018 in China. Hepatology 71, 1851\u20131864 (2020).","journal-title":"Hepatology"},{"key":"961_CR49","doi-asserted-by":"publisher","first-page":"997018","DOI":"10.3389\/fcimb.2022.997018","volume":"12","author":"J Fang","year":"2022","unstructured":"Fang, J. et al. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications. Front Cell Infect. Microbiol 12, 997018 (2022).","journal-title":"Front Cell Infect. Microbiol"},{"key":"961_CR50","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1002\/hep.30946","volume":"70","author":"R Loomba","year":"2019","unstructured":"Loomba, R. & Adams, L. A. The 20% rule of NASH progression: The natural history of advanced fibrosis and cirrhosis caused by NASH. Hepatology 70, 1885\u20131888 (2019).","journal-title":"Hepatology"},{"key":"961_CR51","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","volume":"31","author":"ZM Younossi","year":"2025","unstructured":"Younossi, Z. M., Kalligeros, M. & Henry, L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin. Mol. Hepatol. 31, S32\u2013S50 (2025).","journal-title":"Clin. Mol. Hepatol."},{"key":"961_CR52","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/oby.23073","volume":"29","author":"N You","year":"2021","unstructured":"You, N. et al. Fecal fungi dysbiosis in nonalcoholic fatty liver disease. Obes. (Silver Spring) 29, 350\u2013358 (2021).","journal-title":"Obes. (Silver Spring)"},{"key":"961_CR53","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2307586","volume":"16","author":"G Viebahn","year":"2024","unstructured":"Viebahn, G. et al. Fungal signature differentiates alcohol-associated liver disease from nonalcoholic fatty liver disease. Gut Microbes 16, 2307586 (2024).","journal-title":"Gut Microbes"},{"key":"961_CR54","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3390\/cimb47100847","volume":"47","author":"GGM Scarlata","year":"2025","unstructured":"Scarlata, G. G. M. et al. Gut microbiota changes in metabolic dysfunction-associated steatohepatitis and inflammatory bowel disease: Common pathogenic features. Curr. Issues Mol. Biol. 47, 847 (2025).","journal-title":"Curr. Issues Mol. Biol."},{"key":"961_CR55","doi-asserted-by":"publisher","DOI":"10.1126\/science.adp5540","volume":"388","author":"S Zhou","year":"2025","unstructured":"Zhou, S. et al. A symbiotic filamentous gut fungus ameliorates MASH via a secondary metabolite-CerS6-ceramide axis. Science 388, eadp5540 (2025).","journal-title":"Science"},{"key":"961_CR56","first-page":"921","volume":"24","author":"YT Liu","year":"2016","unstructured":"Liu, Y. T., Li, Y. Q. & Wang, Y. Z. Protective effect of Saccharomyces boulardii against intestinal mucosal barrier injury in rats with nonalcoholic fatty liver disease]. Zhonghua Gan Zang Bing. Za Zhi 24, 921\u2013926 (2016).","journal-title":"Zhonghua Gan Zang Bing. Za Zhi"},{"key":"961_CR57","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1093\/ibd\/izad276","volume":"30","author":"J Cooper","year":"2024","unstructured":"Cooper, J. et al. Incidence and prevalence of primary sclerosing cholangitis: A meta-analysis of population-based studies. Inflamm. Bowel Dis. 30, 2019\u20132026 (2024).","journal-title":"Inflamm. Bowel Dis."},{"key":"961_CR58","doi-asserted-by":"publisher","first-page":"e0322479","DOI":"10.1371\/journal.pone.0322479","volume":"20","author":"M Olfatifar","year":"2025","unstructured":"Olfatifar, M. et al. The epidemiological trends and projected future of primary sclerosing cholangitis by 2040: An updated meta-analysis and modeling study. PLoS One 20, e0322479 (2025).","journal-title":"PLoS One"},{"key":"961_CR59","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1002\/hep.26565","volume":"58","author":"K Boonstra","year":"2013","unstructured":"Boonstra, K. et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 58, 2045\u20132055 (2013).","journal-title":"Hepatology"},{"key":"961_CR60","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1016\/S0140-6736(18)30300-3","volume":"391","author":"JK Dyson","year":"2018","unstructured":"Dyson, J. K., Beuers, U., Jones, D. E. J., Lohse, A. W. & Hudson, M. Primary sclerosing cholangitis. Lancet 391, 2547\u20132559 (2018).","journal-title":"Lancet"},{"key":"961_CR61","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2147\/CEG.S105872","volume":"10","author":"S Sirpal","year":"2017","unstructured":"Sirpal, S. & Chandok, N. Primary sclerosing cholangitis: Diagnostic and management challenges. Clin. Exp. Gastroenterol. 10, 265\u2013273 (2017).","journal-title":"Clin. Exp. Gastroenterol."},{"key":"961_CR62","doi-asserted-by":"publisher","first-page":"814","DOI":"10.14309\/ajg.0000000000000604","volume":"115","author":"A Shah","year":"2020","unstructured":"Shah, A., Macdonald, G. A., Morrison, M. & Holtmann, G. Targeting the gut microbiome as a treatment for primary sclerosing cholangitis: A conceptional framework. Am. J. Gastroenterol. 115, 814\u2013822 (2020).","journal-title":"Am. J. Gastroenterol."},{"key":"961_CR63","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1111\/1462-2920.13401","volume":"18","author":"L-X Lv","year":"2016","unstructured":"Lv, L.-X. et al. Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis. Environ. Microbiol 18, 2272\u20132286 (2016).","journal-title":"Environ. Microbiol"},{"key":"961_CR64","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1136\/gutjnl-2016-313332","volume":"67","author":"R Tang","year":"2018","unstructured":"Tang, R. et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut 67, 534\u2013541 (2018).","journal-title":"Gut"},{"key":"961_CR65","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/hepr.13509","volume":"50","author":"M Furukawa","year":"2020","unstructured":"Furukawa, M. et al. Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis. Hepatol. Res 50, 840\u2013852 (2020).","journal-title":"Hepatol. Res"},{"key":"961_CR66","doi-asserted-by":"publisher","first-page":"e0198757","DOI":"10.1371\/journal.pone.0198757","volume":"13","author":"K Abe","year":"2018","unstructured":"Abe, K. et al. Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease. PLoS One 13, e0198757 (2018).","journal-title":"PLoS One"},{"key":"961_CR67","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3892\/etm.2016.3977","volume":"13","author":"Y Wang","year":"2017","unstructured":"Wang, Y., Zhao, Z., Lu, H., Zhang, J. & Huang, F. Fungal infection involvement in primary biliary cirrhosis: A review of 2 cases. Exp. Ther. Med 13, 489\u2013494 (2017).","journal-title":"Exp. Ther. Med"},{"key":"961_CR68","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/00004836-200304000-00019","volume":"36","author":"DN Samonakis","year":"2003","unstructured":"Samonakis, D. N., Chatzicostas, C., Vardas, E., Roussomoustakaki, M. & Kouroumalis, E. A. Increased incidence of fungal infections in advanced primary biliary cirrhosis. J. Clin. Gastroenterol. 36, 369 (2003).","journal-title":"J. Clin. Gastroenterol."},{"key":"961_CR69","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1046\/j.1365-2249.2003.02166.x","volume":"132","author":"P Muratori","year":"2003","unstructured":"Muratori, P. et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Clin. Exp. Immunol. 132, 473\u2013476 (2003).","journal-title":"Clin. Exp. Immunol."},{"key":"961_CR70","doi-asserted-by":"publisher","first-page":"189","DOI":"10.4132\/jptm.2023.05.24","volume":"57","author":"MJ Lee","year":"2023","unstructured":"Lee, M. J. A review of liver fibrosis and cirrhosis regression. J. Pathol. Transl. Med 57, 189\u2013195 (2023).","journal-title":"J. Pathol. Transl. Med"},{"key":"961_CR71","doi-asserted-by":"publisher","DOI":"10.1126\/science.adj4503","volume":"384","author":"DA Opulente","year":"2024","unstructured":"Opulente, D. A. et al. Genomic factors shape carbon and nitrogen metabolic niche breadth across Saccharomycotina yeasts. Science 384, eadj4503 (2024).","journal-title":"Science"},{"key":"961_CR72","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.jhep.2006.07.022","volume":"45","author":"H Kulaksiz","year":"2006","unstructured":"Kulaksiz, H. et al. Biliary candida infections in primary sclerosing cholangitis. J. Hepatol. 45, 711\u2013716 (2006).","journal-title":"J. Hepatol."},{"key":"961_CR73","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jhep.2009.01.023","volume":"51","author":"G Rudolph","year":"2009","unstructured":"Rudolph, G. et al. Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. J. Hepatol. 51, 149\u2013155 (2009).","journal-title":"J. Hepatol."},{"key":"961_CR74","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.cell.2019.01.041","volume":"176","author":"P Bacher","year":"2019","unstructured":"Bacher, P. et al. Human anti-fungal Th17 immunity and pathology rely on cross-reactivity against candida albicans. Cell 176, 1340\u20131355.e15 (2019).","journal-title":"Cell"},{"key":"961_CR75","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1002\/hep.26447","volume":"58","author":"J Katt","year":"2013","unstructured":"Katt, J. et al. Increased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis. Hepatology 58, 1084\u20131093 (2013).","journal-title":"Hepatology"},{"key":"961_CR76","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1365-2249.2009.03947.x","volume":"157","author":"K Harada","year":"2009","unstructured":"Harada, K. et al. Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis. Clin. Exp. Immunol. 157, 261\u2013270 (2009).","journal-title":"Clin. Exp. Immunol."},{"key":"961_CR77","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jaut.2008.11.001","volume":"32","author":"RYZ Lan","year":"2009","unstructured":"Lan, R. Y. Z. et al. Hepatic IL-17 responses in human and murine primary biliary cirrhosis. J. Autoimmun. 32, 43\u201351 (2009).","journal-title":"J. Autoimmun."},{"key":"961_CR78","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","volume":"72","author":"A Albillos","year":"2020","unstructured":"Albillos, A., de Gottardi, A. & Rescigno, M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J. Hepatol. 72, 558\u2013577 (2020).","journal-title":"J. Hepatol."},{"key":"961_CR79","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1159\/000490262","volume":"34","author":"J Trebicka","year":"2018","unstructured":"Trebicka, J., Reiberger, T. & Laleman, W. Gut-liver axis links portal hypertension to acute-on-chronic liver failure. Visc. Med. 34, 270\u2013275 (2018).","journal-title":"Visc. Med."},{"key":"961_CR80","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1055\/s-2008-1040319","volume":"28","author":"P Tandon","year":"2008","unstructured":"Tandon, P. & Garcia-Tsao, G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis. 28, 26\u201342 (2008).","journal-title":"Semin Liver Dis."},{"key":"961_CR81","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.3748\/wjg.v24.i38.4311","volume":"24","author":"E Righi","year":"2018","unstructured":"Righi, E. Management of bacterial and fungal infections in end stage liver disease and liver transplantation: Current options and future directions. World J. Gastroenterol. 24, 4311\u20134329 (2018).","journal-title":"World J. Gastroenterol."},{"key":"961_CR82","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11046-014-9825-6","volume":"179","author":"T Lahmer","year":"2015","unstructured":"Lahmer, T. et al. Fungal \u2018colonisation\u2019 is associated with increased mortality in medical intensive care unit patients with liver cirrhosis. Mycopathologia 179, 63\u201371 (2015).","journal-title":"Mycopathologia"},{"key":"961_CR83","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1136\/gutjnl-2016-313170","volume":"67","author":"JS Bajaj","year":"2018","unstructured":"Bajaj, J. S. et al. Fungal dysbiosis in cirrhosis. Gut 67, 1146\u20131154 (2018).","journal-title":"Gut"},{"key":"961_CR84","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myad071","volume":"61","author":"CM Perlin","year":"2023","unstructured":"Perlin, C. M., Longo, L., Keingeski, M. B., Picon, R. V. & \u00c1lvares-da-Silva, M. R. Gut mycobiota changes in liver diseases: A systematic review. Med Mycol. 61, myad071 (2023).","journal-title":"Med Mycol."},{"key":"961_CR85","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.diagmicrobio.2010.04.005","volume":"70","author":"Y Chen","year":"2011","unstructured":"Chen, Y. et al. Correlation between gastrointestinal fungi and varying degrees of chronic hepatitis B virus infection. Diagn. Microbiol Infect. Dis. 70, 492\u2013498 (2011).","journal-title":"Diagn. Microbiol Infect. Dis."},{"key":"961_CR86","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.amjmed.2005.06.070","volume":"119","author":"WB Park","year":"2006","unstructured":"Park, W. B. et al. Spontaneous cryptococcal peritonitis in patients with liver cirrhosis. Am. J. Med 119, 169\u2013171 (2006).","journal-title":"Am. J. Med"},{"key":"961_CR87","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1097\/MEG.0000000000000927","volume":"29","author":"M Gravito-Soares","year":"2017","unstructured":"Gravito-Soares, M., Gravito-Soares, E., Lopes, S., Ribeiro, G. & Figueiredo, P. Spontaneous fungal peritonitis: a rare but severe complication of liver cirrhosis. Eur. J. Gastroenterol. Hepatol. 29, 1010\u20131016 (2017).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"961_CR88","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jhep.2014.03.021","volume":"61","author":"M Bartoletti","year":"2014","unstructured":"Bartoletti, M. et al. Epidemiology and outcomes of bloodstream infection in patients with cirrhosis. J. Hepatol. 61, 51\u201358 (2014).","journal-title":"J. Hepatol."},{"key":"961_CR89","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/ajg.2017.471","volume":"113","author":"JS Bajaj","year":"2018","unstructured":"Bajaj, J. S. et al. Prediction of fungal infection development and their impact on survival using the NACSELD cohort. Am. J. Gastroenterol. 113, 556\u2013563 (2018).","journal-title":"Am. J. Gastroenterol."},{"key":"961_CR90","doi-asserted-by":"publisher","first-page":"e12957","DOI":"10.1371\/journal.pone.0012957","volume":"5","author":"M Papp","year":"2010","unstructured":"Papp, M. et al. Presence of anti-microbial antibodies in liver cirrhosis-a tell-tale sign of compromised immunity? PLoS One 5, e12957 (2010).","journal-title":"PLoS One"},{"key":"961_CR91","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s10096-013-1953-2","volume":"33","author":"SY Hwang","year":"2014","unstructured":"Hwang, S. Y. et al. Spontaneous fungal peritonitis: A severe complication in patients with advanced liver cirrhosis. Eur. J. Clin. Microbiol Infect. Dis. 33, 259\u2013264 (2014).","journal-title":"Eur. J. Clin. Microbiol Infect. Dis."},{"key":"961_CR92","doi-asserted-by":"publisher","first-page":"e0158389","DOI":"10.1371\/journal.pone.0158389","volume":"11","author":"T Lahmer","year":"2016","unstructured":"Lahmer, T., Brandl, A., Rasch, S., Schmid, R. M. & Huber, W. Fungal peritonitis: Underestimated disease in critically ill patients with liver cirrhosis and spontaneous peritonitis. PLoS One 11, e0158389 (2016).","journal-title":"PLoS One"},{"key":"961_CR93","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Prim. 7, 6 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"961_CR94","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.pharmthera.2017.02.010","volume":"173","author":"R Dutta","year":"2017","unstructured":"Dutta, R. & Mahato, R. I. Recent advances in hepatocellular carcinoma therapy. Pharm. Ther. 173, 106\u2013117 (2017).","journal-title":"Pharm. Ther."},{"key":"961_CR95","doi-asserted-by":"publisher","first-page":"m3544","DOI":"10.1136\/bmj.m3544","volume":"371","author":"JD Yang","year":"2020","unstructured":"Yang, J. D. & Heimbach, J. K. New advances in the diagnosis and management of hepatocellular carcinoma. BMJ 371, m3544 (2020).","journal-title":"BMJ"},{"key":"961_CR96","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jhep.2017.03.011","volume":"67","author":"P Bertuccio","year":"2017","unstructured":"Bertuccio, P. et al. Global trends and predictions in hepatocellular carcinoma mortality. J. Hepatol. 67, 302\u2013309 (2017).","journal-title":"J. Hepatol."},{"key":"961_CR97","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3350\/cmh.2025.0315","volume":"32","author":"Y Xie","year":"2026","unstructured":"Xie, Y. et al. GULP1, a multifaceted diagnostic biomarker and potential therapeutic target in hepatocellular carcinoma: Editorial on \u2018GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma. Clin. Mol. Hepatol. 32, 413\u2013415 (2026).","journal-title":"Clin. Mol. Hepatol."},{"key":"961_CR98","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3350\/cmh.2025.0515","volume":"32","author":"JE Han","year":"2026","unstructured":"Han, J. E. et al. Uncovering the MET-TRIB3-FOXO1 axis: A novel target in MET-driven hepatocellular carcinoma: Editorial on \u2018MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation. Clin. Mol. Hepatol. 32, 436\u2013438 (2026).","journal-title":"Clin. Mol. Hepatol."},{"key":"961_CR99","first-page":"305","volume":"22","author":"MC Kew","year":"2013","unstructured":"Kew, M. C. Aflatoxins as a cause of hepatocellular carcinoma. J. Gastrointestin Liver Dis. 22, 305\u2013310 (2013).","journal-title":"J. Gastrointestin Liver Dis."},{"key":"961_CR100","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s11427-023-2458-1","volume":"67","author":"S Jiang","year":"2024","unstructured":"Jiang, S. et al. Longitudinal gut fungal alterations and potential fungal biomarkers for the progression of primary liver disease. Sci. China Life Sci. 67, 1183\u20131198 (2024).","journal-title":"Sci. China Life Sci."},{"key":"961_CR101","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-03940-y","volume":"21","author":"L Zhang","year":"2023","unstructured":"Zhang, L. et al. Characterization of the intestinal fungal microbiome in patients with hepatocellular carcinoma. J. Transl. Med 21, 126 (2023).","journal-title":"J. Transl. Med"},{"key":"961_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.812771","volume":"13","author":"Z Liu","year":"2022","unstructured":"Liu, Z. et al. Intestinal Candida albicans Promotes Hepatocarcinogenesis by Up-Regulating NLRP6. Front Microbiol 13, 812771 (2022).","journal-title":"Front Microbiol"},{"key":"961_CR103","doi-asserted-by":"publisher","first-page":"100220","DOI":"10.1016\/j.jhepr.2020.100220","volume":"3","author":"B Fairfield","year":"2021","unstructured":"Fairfield, B. & Schnabl, B. Gut dysbiosis as a driver in alcohol-induced liver injury. JHEP Rep. 3, 100220 (2021).","journal-title":"JHEP Rep."},{"key":"961_CR104","doi-asserted-by":"publisher","first-page":"e0029","DOI":"10.1097\/HC9.0000000000000029","volume":"7","author":"S Zeng","year":"2023","unstructured":"Zeng, S. et al. Malassezia restricta promotes alcohol-induced liver injury. Hepatol. Commun. 7, e0029 (2023).","journal-title":"Hepatol. Commun."},{"key":"961_CR105","first-page":"1713","volume":"60","author":"M Ulusan","year":"2024","unstructured":"Ulusan, M. et al. Saccharomyces boulardii mitigates fructose-induced non-alcoholic fatty liver in rats. Med. (Kaunas.) 60, 1713 (2024).","journal-title":"Med. (Kaunas.)"},{"key":"961_CR106","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-01271-9","volume":"7","author":"L Yu","year":"2017","unstructured":"Yu, L. et al. Saccharomyces boulardii administration changes gut microbiota and attenuates D-galactosamine-induced liver injury. Sci. Rep. 7, 1359 (2017).","journal-title":"Sci. Rep."},{"key":"961_CR107","doi-asserted-by":"publisher","first-page":"D791","DOI":"10.1093\/nar\/gkad1039","volume":"52","author":"K Abarenkov","year":"2024","unstructured":"Abarenkov, K. et al. The UNITE database for molecular identification and taxonomic communication of fungi and other eukaryotes: Sequences, taxa and classifications reconsidered. Nucleic Acids Res. 52, D791\u2013D797 (2024).","journal-title":"Nucleic Acids Res."},{"key":"961_CR108","doi-asserted-by":"publisher","first-page":"90","DOI":"10.14806\/ej.18.A.430","volume":"18","author":"B Fosso","year":"2012","unstructured":"Fosso, B. et al. ITSoneDB: a specialized ITS1 database for amplicon-based metagenomic characterization of environmental fungal communities. EMBnet. J. 18, 90 (2012).","journal-title":"EMBnet. J."},{"key":"961_CR109","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.3852\/15-147","volume":"107","author":"MJ Suhr","year":"2015","unstructured":"Suhr, M. J. & Hallen-Adams, H. E. The human gut mycobiome: pitfalls and potentials-a mycologist\u2019s perspective. Mycologia 107, 1057\u20131073 (2015).","journal-title":"Mycologia"},{"key":"961_CR110","doi-asserted-by":"publisher","first-page":"67","DOI":"10.4103\/ejpi.EJPI-D-24-00090","volume":"68","author":"HT Doan","year":"2025","unstructured":"Doan, H. T. et al. Candida tropicalis alters barrier permeability and claudin-1 organization in intestinal epithelial cells. J. Physiol. Investig. 68, 67 (2025).","journal-title":"J. Physiol. Investig."},{"key":"961_CR111","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3390\/toxins17020089","volume":"17","author":"M Morelli","year":"2025","unstructured":"Morelli, M. & Queiroz, K. Breaking Barriers: Candidalysin disrupts epithelial integrity and induces inflammation in a gut-on-chip model. Toxins (Basel) 17, 89 (2025).","journal-title":"Toxins (Basel)"},{"key":"961_CR112","doi-asserted-by":"publisher","unstructured":"Allert, S. et al. Candida albicans-induced epithelial damage mediates translocation through intestinal barriers. mBio 9, https:\/\/doi.org\/10.1128\/mbio.00915-18 (2018).","DOI":"10.1128\/mbio.00915-18"},{"key":"961_CR113","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.jcmgh.2023.12.005","volume":"17","author":"B \u00d6zdirik","year":"2024","unstructured":"\u00d6zdirik, B. & Schnabl, B. Microbial players in primary sclerosing cholangitis: Current evidence and concepts. Cell Mol. Gastroenterol. Hepatol. 17, 423\u2013438 (2024).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"961_CR114","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nri2939","volume":"11","author":"L Romani","year":"2011","unstructured":"Romani, L. Immunity to fungal infections. Nat. Rev. Immunol. 11, 275\u2013288 (2011).","journal-title":"Nat. Rev. Immunol."},{"key":"961_CR115","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S1074-7613(03)00233-4","volume":"19","author":"GD Brown","year":"2003","unstructured":"Brown, G. D. & Gordon, S. Fungal beta-glucans and mammalian immunity. Immunity 19, 311\u2013315 (2003).","journal-title":"Immunity"},{"key":"961_CR116","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00281-014-0462-4","volume":"37","author":"A Plato","year":"2015","unstructured":"Plato, A. et al. Pattern recognition receptors in antifungal immunity. Semin Immunopathol. 37, 97\u2013106 (2015).","journal-title":"Semin Immunopathol."},{"key":"961_CR117","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1128\/JCM.01737-13","volume":"51","author":"ES Theel","year":"2013","unstructured":"Theel, E. S. & Doern, C. D. \u03b2-D-glucan testing is important for diagnosis of invasive fungal infections. J. Clin. Microbiol 51, 3478\u20133483 (2013).","journal-title":"J. Clin. Microbiol"},{"key":"961_CR118","first-page":"344","volume":"11","author":"N Kondori","year":"2004","unstructured":"Kondori, N., Edebo, L. & Mattsby-Baltzer, I. Circulating beta (1-3) glucan and immunoglobulin G subclass antibodies to Candida albicans cell wall antigens in patients with systemic candidiasis. Clin. Diagn. Lab Immunol. 11, 344\u2013350 (2004).","journal-title":"Clin. Diagn. Lab Immunol."},{"key":"961_CR119","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/hep.22306","volume":"48","author":"E Seki","year":"2008","unstructured":"Seki, E. & Brenner, D. A. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 48, 322\u2013335 (2008).","journal-title":"Hepatology"},{"key":"961_CR120","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.840752","volume":"9","author":"L Chen","year":"2022","unstructured":"Chen, L. et al. The role of gut bacteria and fungi in alcohol-associated liver disease. Front Med (Lausanne) 9, 840752 (2022).","journal-title":"Front Med (Lausanne)"},{"key":"961_CR121","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/nri.2017.55","volume":"17","author":"ID Iliev","year":"2017","unstructured":"Iliev, I. D. & Leonardi, I. Fungal dysbiosis: Immunity and interactions at mucosal barriers. Nat. Rev. Immunol. 17, 635\u2013646 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"961_CR122","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41590-019-0377-2","volume":"20","author":"RA Drummond","year":"2019","unstructured":"Drummond, R. A. et al. CARD9+ microglia promote antifungal immunity via IL-1\u03b2- and CXCL1-mediated neutrophil recruitment. Nat. Immunol. 20, 559\u2013570 (2019).","journal-title":"Nat. Immunol."},{"key":"961_CR123","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s10020-019-0084-3","volume":"25","author":"A-M Mirea","year":"2019","unstructured":"Mirea, A.-M. et al. Increased proteinase 3 and neutrophil elastase plasma concentrations are associated with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes. Mol. Med 25, 16 (2019).","journal-title":"Mol. Med"},{"key":"961_CR124","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.3390\/nu15092068","volume":"15","author":"DW Ma","year":"2023","unstructured":"Ma, D. W. et al. Innate immune system in the pathogenesis of non-alcoholic fatty liver disease. Nutrients 15, 2068 (2023).","journal-title":"Nutrients"},{"key":"961_CR125","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.3390\/cells11213390","volume":"11","author":"B Mbaye","year":"2022","unstructured":"Mbaye, B. et al. Endogenous ethanol and triglyceride production by gut pichia kudriavzevii, candida albicans and candida glabrata yeasts in non-alcoholic steatohepatitis. Cells 11, 3390 (2022).","journal-title":"Cells"},{"key":"961_CR126","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s42003-021-01820-z","volume":"4","author":"TS Mims","year":"2021","unstructured":"Mims, T. S. et al. The gut mycobiome of healthy mice is shaped by the environment and correlates with metabolic outcomes in response to diet. Commun. Biol. 4, 281 (2021).","journal-title":"Commun. Biol."},{"key":"961_CR127","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/j.1740-0929.2012.01035.x","volume":"84","author":"Wulijideligen Sudun","year":"2013","unstructured":"Sudun, W. ulijideligen, Arakawa, K., Miyamoto, M. & Miyamoto, T. Interaction between lactic acid bacteria and yeasts in airag, an alcoholic fermented milk. Anim. Sci. J. 84, 66\u201374 (2013).","journal-title":"Anim. Sci. J."},{"key":"961_CR128","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1365-2672.1985.tb01473.x","volume":"58","author":"WS Bivin","year":"1985","unstructured":"Bivin, W. S. & Heinen, B. N. Production of ethanol from infant food formulas by common yeasts. J. Appl Bacteriol. 58, 355\u2013357 (1985).","journal-title":"J. Appl Bacteriol."},{"key":"961_CR129","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/ueg2.12062","volume":"9","author":"AB Bayoumy","year":"2021","unstructured":"Bayoumy, A. B., Mulder, C. J. J., Mol, J. J. & Tushuizen, M. E. Gut fermentation syndrome: A systematic review of case reports. U. Eur. Gastroenterol. J. 9, 332\u2013342 (2021).","journal-title":"U. Eur. Gastroenterol. J."},{"key":"961_CR130","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4161\/21505594.2014.988097","volume":"6","author":"Z Gr\u00f3zer","year":"2015","unstructured":"Gr\u00f3zer, Z. et al. Candida parapsilosis produces prostaglandins from exogenous arachidonic acid and OLE2 is not required for their synthesis. Virulence 6, 85\u201392 (2015).","journal-title":"Virulence"},{"key":"961_CR131","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1128\/IAI.69.5.2957-2963.2001","volume":"69","author":"MC Noverr","year":"2001","unstructured":"Noverr, M. C., Phare, S. M., Toews, G. B., Coffey, M. J. & Huffnagle, G. B. Pathogenic yeasts Cryptococcus neoformans and Candida albicans produce immunomodulatory prostaglandins. Infect. Immun. 69, 2957\u20132963 (2001).","journal-title":"Infect. Immun."},{"key":"961_CR132","doi-asserted-by":"publisher","first-page":"1830693","DOI":"10.1080\/19490976.2020.1830693","volume":"12","author":"S Sun","year":"2020","unstructured":"Sun, S. et al. Therapeutic manipulation of gut microbiota by polysaccharides of Wolfiporia cocos reveals the contribution of the gut fungi-induced PGE2 to alcoholic hepatic steatosis. Gut Microbes 12, 1830693 (2020).","journal-title":"Gut Microbes"},{"key":"961_CR133","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3892\/ijmm.2021.4947","volume":"47","author":"W Wang","year":"2021","unstructured":"Wang, W., Zhong, X. & Guo, J. Role of 2\u2011series prostaglandins in the pathogenesis of type 2 diabetes mellitus and non\u2011alcoholic fatty liver disease (Review). Int J. Mol. Med 47, 114 (2021).","journal-title":"Int J. Mol. Med"},{"key":"961_CR134","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-34633-y","volume":"8","author":"J Henkel","year":"2018","unstructured":"Henkel, J. et al. Augmented liver inflammation in a microsomal prostaglandin E synthase 1 (mPGES-1)-deficient diet-induced mouse NASH model. Sci. Rep. 8, 16127 (2018).","journal-title":"Sci. Rep."},{"key":"961_CR135","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1093\/intimm\/dxq442","volume":"22","author":"SP Smeekens","year":"2010","unstructured":"Smeekens, S. P. et al. The Candida Th17 response is dependent on mannan- and beta-glucan-induced prostaglandin E2. Int Immunol. 22, 889\u2013895 (2010).","journal-title":"Int Immunol."},{"key":"961_CR136","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1189\/jlb.0310139","volume":"88","author":"MC Gagliardi","year":"2010","unstructured":"Gagliardi, M. C. et al. Endogenous PGE2 promotes the induction of human Th17 responses by fungal \u00df-glucan. J. Leukoc. Biol. 88, 947\u2013954 (2010).","journal-title":"J. Leukoc. Biol."},{"key":"961_CR137","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/cmi.2010.5","volume":"7","author":"F Lafdil","year":"2010","unstructured":"Lafdil, F., Miller, A. M., Ki, S. H. & Gao, B. Th17 cells and their associated cytokines in liver diseases. Cell Mol. Immunol. 7, 250\u2013254 (2010).","journal-title":"Cell Mol. Immunol."},{"key":"961_CR138","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06607-1","volume":"9","author":"L Kasper","year":"2018","unstructured":"Kasper, L. et al. The fungal peptide toxin Candidalysin activates the NLRP3 inflammasome and causes cytolysis in mononuclear phagocytes. Nat. Commun. 9, 4260 (2018).","journal-title":"Nat. Commun."},{"key":"961_CR139","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","volume":"66","author":"AR Mridha","year":"2017","unstructured":"Mridha, A. R. et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J. Hepatol. 66, 1037\u20131046 (2017).","journal-title":"J. Hepatol."},{"key":"961_CR140","doi-asserted-by":"publisher","first-page":"37657","DOI":"10.18632\/oncotarget.17489","volume":"8","author":"K He","year":"2017","unstructured":"He, K. et al. Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease development. Oncotarget 8, 37657\u201337672 (2017).","journal-title":"Oncotarget"},{"key":"961_CR141","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.3748\/wjg.v19.i10.1508","volume":"19","author":"A Magnussen","year":"2013","unstructured":"Magnussen, A. & Parsi, M. A. Aflatoxins, hepatocellular carcinoma and public health. World J. Gastroenterol. 19, 1508\u20131512 (2013).","journal-title":"World J. Gastroenterol."},{"key":"961_CR142","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.3892\/ol.2013.1169","volume":"5","author":"AS Hamid","year":"2013","unstructured":"Hamid, A. S., Tesfamariam, I. G., Zhang, Y. & Zhang, Z. G. Aflatoxin B1-induced hepatocellular carcinoma in developing countries: Geographical distribution, mechanism of action and prevention. Oncol. Lett. 5, 1087\u20131092 (2013).","journal-title":"Oncol. Lett."},{"key":"961_CR143","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1478-3231.2003.00869.x","volume":"23","author":"MC Kew","year":"2003","unstructured":"Kew, M. C. Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int 23, 405\u2013409 (2003).","journal-title":"Liver Int"},{"key":"961_CR144","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00351-17","volume":"2","author":"T Heisel","year":"2017","unstructured":"Heisel, T. et al. High-fat diet changes fungal microbiomes and interkingdom relationships in the murine gut. mSphere 2, e00351-17 (2017).","journal-title":"mSphere"},{"key":"961_CR145","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3389\/fcimb.2020.00105","volume":"10","author":"M Fern\u00e1ndez de Ullivarri","year":"2020","unstructured":"Fern\u00e1ndez de Ullivarri, M., Arbulu, S., Garcia-Gutierrez, E. & Cotter, P. D. Antifungal peptides as therapeutic agents. Front Cell Infect. Microbiol 10, 105 (2020).","journal-title":"Front Cell Infect. Microbiol"},{"key":"961_CR146","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/s41396-018-0293-8","volume":"13","author":"A Kombrink","year":"2019","unstructured":"Kombrink, A. et al. Induction of antibacterial proteins and peptides in the coprophilous mushroom Coprinopsis cinerea in response to bacteria. ISME J. 13, 588\u2013602 (2019).","journal-title":"ISME J."},{"key":"961_CR147","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.chom.2019.02.004","volume":"25","author":"T-Y Shao","year":"2019","unstructured":"Shao, T.-Y. et al. Commensal candida albicans positively calibrates systemic Th17 immunological responses. Cell Host Microbe 25, 404\u2013417.e6 (2019).","journal-title":"Cell Host Microbe"},{"key":"961_CR148","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.add6910","volume":"8","author":"Y-H Chen","year":"2023","unstructured":"Chen, Y.-H. et al. Rewilding of laboratory mice enhances granulopoiesis and immunity through intestinal fungal colonization. Sci. Immunol. 8, eadd6910 (2023).","journal-title":"Sci. Immunol."},{"key":"961_CR149","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00555-17","volume":"2","author":"C Garc\u00eda","year":"2017","unstructured":"Garc\u00eda, C. et al. The human gut microbial metabolome modulates fungal growth via the TOR signaling pathway. mSphere 2, e00555-17 (2017).","journal-title":"mSphere"},{"key":"961_CR150","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30661-5","volume":"13","author":"R Alonso-Roman","year":"2022","unstructured":"Alonso-Roman, R. et al. Lactobacillus rhamnosus colonisation antagonizes Candida albicans by forcing metabolic adaptations that compromise pathogenicity. Nat. Commun. 13, 3192 (2022).","journal-title":"Nat. Commun."},{"key":"961_CR151","doi-asserted-by":"publisher","first-page":"6206","DOI":"10.1128\/IAI.72.11.6206-6210.2004","volume":"72","author":"MC Noverr","year":"2004","unstructured":"Noverr, M. C. & Huffnagle, G. B. Regulation of Candida albicans morphogenesis by fatty acid metabolites. Infect. Immun. 72, 6206\u20136210 (2004).","journal-title":"Infect. Immun."},{"key":"961_CR152","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1146\/annurev.med.59.110106.132000","volume":"59","author":"AS Lynch","year":"2008","unstructured":"Lynch, A. S. & Robertson, G. T. Bacterial and fungal biofilm infections. Annu Rev. Med 59, 415\u2013428 (2008).","journal-title":"Annu Rev. Med"},{"key":"961_CR153","doi-asserted-by":"crossref","first-page":"e00187","DOI":"10.1128\/mSphere.00187-16","volume":"1","author":"PT van Leeuwen","year":"2016","unstructured":"van Leeuwen, P. T. et al. Interspecies Interactions between Clostridium difficile and Candida albicans. mSphere 1, e00187\u201316 (2016).","journal-title":"mSphere"},{"key":"961_CR154","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13578-023-00974-z","volume":"13","author":"L Chen","year":"2023","unstructured":"Chen, L. et al. Modulating phenylalanine metabolism by L. acidophilus alleviates alcohol-related liver disease through enhancing intestinal barrier function. Cell Biosci. 13, 24 (2023).","journal-title":"Cell Biosci."},{"key":"961_CR155","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.3390\/ijms26094077","volume":"26","author":"W Wang","year":"2025","unstructured":"Wang, W., Gao, X., Niu, W., Yin, J. & He, K. Targeting Metabolism: Innovative Therapies for MASLD Unveiled. Int J. Mol. Sci. 26, 4077 (2025).","journal-title":"Int J. Mol. Sci."},{"key":"961_CR156","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3350\/cmh.2025.0083","volume":"31","author":"HY Kim","year":"2025","unstructured":"Kim, H. Y. & Rinella, M. E. Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment. Clin. Mol. Hepatol. 31, 753\u2013770 (2025).","journal-title":"Clin. Mol. Hepatol."},{"key":"961_CR157","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000443359","volume":"34","author":"H Szajewska","year":"2016","unstructured":"Szajewska, H., Konarska, Z. & Ko\u0142odziej, M. Probiotic bacterial and fungal strains: Claims with evidence. Dig. Dis. 34, 251\u2013259 (2016).","journal-title":"Dig. Dis."},{"key":"961_CR158","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1017\/S000711451200517X","volume":"110","author":"DG Duman","year":"2013","unstructured":"Duman, D. G. et al. Saccharomyces boulardii ameliorates clarithromycin- and methotrexate-induced intestinal and hepatic injury in rats. Br. J. Nutr. 110, 493\u2013499 (2013).","journal-title":"Br. J. Nutr."},{"key":"961_CR159","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s10753-014-0019-7","volume":"38","author":"M Li","year":"2015","unstructured":"Li, M., Zhu, L., Xie, A. & Yuan, J. Oral administration of Saccharomyces boulardii ameliorates carbon tetrachloride-induced liver fibrosis in rats via reducing intestinal permeability and modulating gut microbial composition. Inflammation 38, 170\u2013179 (2015).","journal-title":"Inflammation"},{"key":"961_CR160","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3389\/fmicb.2016.00647","volume":"7","author":"BCT Bourrie","year":"2016","unstructured":"Bourrie, B. C. T., Willing, B. P. & Cotter, P. D. The microbiota and health promoting characteristics of the fermented beverage kefir. Front Microbiol 7, 647 (2016).","journal-title":"Front Microbiol"},{"key":"961_CR161","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.3168\/jds.2021-21382","volume":"105","author":"BD Gonz\u00e1lez-Orozco","year":"2022","unstructured":"Gonz\u00e1lez-Orozco, B. D., Garc\u00eda-Cano, I., Jim\u00e9nez-Flores, R. & Alv\u00e1rez, V. B. Invited review: Milk kefir microbiota-Direct and indirect antimicrobial effects. J. Dairy Sci. 105, 3703\u20133715 (2022).","journal-title":"J. Dairy Sci."},{"key":"961_CR162","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1056\/NEJMoa1714373","volume":"379","author":"DW Eyre","year":"2018","unstructured":"Eyre, D. W. et al. A candida auris outbreak and its control in an intensive care setting. N. Engl. J. Med 379, 1322\u20131331 (2018).","journal-title":"N. Engl. J. Med"},{"key":"961_CR163","doi-asserted-by":"publisher","first-page":"165rv13","DOI":"10.1126\/scitranslmed.3004404","volume":"4","author":"GD Brown","year":"2012","unstructured":"Brown, G. D. et al. Hidden killers: human fungal infections. Sci. Transl. Med 4, 165rv13 (2012).","journal-title":"Sci. Transl. Med"},{"key":"961_CR164","doi-asserted-by":"crossref","unstructured":"Robbins, N., Wright, G. D. & Cowen, L. E. Antifungal drugs: the current armamentarium and development of new agents. Microbiol. Spectr. 4, 903\u2013922 (2016).","DOI":"10.1128\/9781555819583.ch44"},{"key":"961_CR165","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2440111","volume":"16","author":"H Huang","year":"2024","unstructured":"Huang, H. et al. The mycobiome as integral part of the gut microbiome: crucial role of symbiotic fungi in health and disease. Gut Microbes 16, 2440111 (2024).","journal-title":"Gut Microbes"},{"key":"961_CR166","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/s42003-023-04591-x","volume":"6","author":"L Bao","year":"2023","unstructured":"Bao, L., Zhang, Y., Zhang, G., Jiang, D. & Yan, D. Abnormal proliferation of gut mycobiota contributes to the aggravation of Type 2 diabetes. Commun. Biol. 6, 226 (2023).","journal-title":"Commun. Biol."},{"key":"961_CR167","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.chom.2018.11.003","volume":"24","author":"X Li","year":"2018","unstructured":"Li, X. et al. Response to fungal dysbiosis by gut-resident CX3CR1+ mononuclear phagocytes aggravates allergic airway disease. Cell Host Microbe 24, 847\u2013856.e4 (2018).","journal-title":"Cell Host Microbe"},{"key":"961_CR168","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.chom.2016.05.003","volume":"19","author":"ML Wheeler","year":"2016","unstructured":"Wheeler, M. L. et al. Immunological consequences of intestinal fungal dysbiosis. Cell Host Microbe 19, 865\u2013873 (2016).","journal-title":"Cell Host Microbe"},{"key":"961_CR169","first-page":"e18940","volume":"13","author":"E Gadour","year":"2021","unstructured":"Gadour, E. & Kotb, A. Systematic review of antifungal-induced acute liver failure. Cureus 13, e18940 (2021).","journal-title":"Cureus"},{"key":"961_CR170","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3390\/jof4040133","volume":"4","author":"N Spernovasilis","year":"2018","unstructured":"Spernovasilis, N. & Kofteridis, D. P. Pre-existing liver disease and toxicity of antifungals. J. Fungi (Basel) 4, 133 (2018).","journal-title":"J. Fungi (Basel)"},{"key":"961_CR171","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.14309\/ajg.0000000000000661","volume":"115","author":"L Craven","year":"2020","unstructured":"Craven, L. et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: A randomized control trial. Am. J. Gastroenterol. 115, 1055\u20131065 (2020).","journal-title":"Am. J. Gastroenterol."},{"key":"961_CR172","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.14309\/ajg.0000000000000115","volume":"114","author":"JR Allegretti","year":"2019","unstructured":"Allegretti, J. R. et al. Fecal microbiota transplantation in patients with primary sclerosing cholangitis: A pilot clinical trial. Am. J. Gastroenterol. 114, 1071\u20131079 (2019).","journal-title":"Am. J. Gastroenterol."},{"key":"961_CR173","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s10620-020-06246-x","volume":"66","author":"A Chauhan","year":"2021","unstructured":"Chauhan, A. et al. Fecal microbiota transplantation in hepatitis B e antigen-positive chronic Hepatitis B patients: A pilot study. Dig. Dis. Sci. 66, 873\u2013880 (2021).","journal-title":"Dig. Dis. Sci."},{"key":"961_CR174","doi-asserted-by":"publisher","first-page":"67","DOI":"10.31083\/j.fbl2902067","volume":"29","author":"S Acharya","year":"2024","unstructured":"Acharya, S. & Thirunavukkarasu, C. Gut microbiome and cancer: From cancer development to therapeutics with a special focus on hepatocellular carcinoma. Front Biosci. (Landmark Ed.) 29, 67 (2024).","journal-title":"Front Biosci. (Landmark Ed.)"},{"key":"961_CR175","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1002\/hep.30690","volume":"70","author":"JS Bajaj","year":"2019","unstructured":"Bajaj, J. S. et al. Fecal microbial transplant capsules are safe in hepatic encephalopathy: A phase 1, randomized, placebo-controlled trial. Hepatology 70, 1690\u20131703 (2019).","journal-title":"Hepatology"},{"key":"961_CR176","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.jceh.2022.01.001","volume":"12","author":"CA Philips","year":"2022","unstructured":"Philips, C. A., Ahamed, R., Rajesh, S., Abduljaleel, J. K. P. & Augustine, P. Long-term outcomes of stool transplant in alcohol-associated hepatitis-analysis of clinical outcomes, relapse, gut microbiota and comparisons with standard care. J. Clin. Exp. Hepatol. 12, 1124\u20131132 (2022).","journal-title":"J. Clin. Exp. Hepatol."},{"key":"961_CR177","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.cgh.2016.10.029","volume":"15","author":"CA Philips","year":"2017","unstructured":"Philips, C. A. et al. Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: A pilot study. Clin. Gastroenterol. Hepatol. 15, 600\u2013602 (2017).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"961_CR178","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s12072-022-10312-z","volume":"16","author":"A Sharma","year":"2022","unstructured":"Sharma, A. et al. Fecal microbiota transplantation in alcohol-associated acute-on-chronic liver failure: an open-label clinical trial. Hepatol. Int 16, 433\u2013446 (2022).","journal-title":"Hepatol. Int"},{"key":"961_CR179","doi-asserted-by":"publisher","first-page":"759306","DOI":"10.3389\/fcimb.2022.759306","volume":"12","author":"L Xue","year":"2022","unstructured":"Xue, L., Deng, Z., Luo, W., He, X. & Chen, Y. Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: A randomized clinical trial. Front Cell Infect. Microbiol 12, 759306 (2022).","journal-title":"Front Cell Infect. Microbiol"},{"key":"961_CR180","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.chom.2023.03.019","volume":"31","author":"A Yadegar","year":"2023","unstructured":"Yadegar, A. et al. Beneficial effects of fecal microbiota transplantation in recurrent Clostridioides difficile infection. Cell Host Microbe 31, 695\u2013711 (2023).","journal-title":"Cell Host Microbe"},{"key":"961_CR181","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/path.4983","volume":"243","author":"L Sheng","year":"2017","unstructured":"Sheng, L. et al. Hepatic inflammation caused by dysregulated bile acid synthesis is reversible by butyrate supplementation. J. Pathol. 243, 431\u2013441 (2017).","journal-title":"J. Pathol."},{"key":"961_CR182","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06103-6","volume":"9","author":"T Zuo","year":"2018","unstructured":"Zuo, T. et al. Gut fungal dysbiosis correlates with reduced efficacy of fecal microbiota transplantation in Clostridium difficile infection. Nat. Commun. 9, 3663 (2018).","journal-title":"Nat. Commun."},{"key":"961_CR183","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41575-021-00441-5","volume":"18","author":"C Danne","year":"2021","unstructured":"Danne, C., Rolhion, N. & Sokol, H. Recipient factors in faecal microbiota transplantation: one stool does not fit all. Nat. Rev. Gastroenterol. Hepatol. 18, 503\u2013513 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"961_CR184","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1056\/NEJMoa1910437","volume":"381","author":"Z DeFilipp","year":"2019","unstructured":"DeFilipp, Z. et al. Drug-Resistant E. coli bacteremia transmitted by fecal microbiota transplant. N. Engl. J. Med. 381, 2043\u20132050 (2019).","journal-title":"N. Engl. J. Med."},{"key":"961_CR185","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.jhep.2021.12.003","volume":"76","author":"JS Bajaj","year":"2022","unstructured":"Bajaj, J. S., Ng, S. C. & Schnabl, B. Promises of microbiome-based therapies. J. Hepatol. 76, 1379\u20131391 (2022).","journal-title":"J. Hepatol."},{"key":"961_CR186","doi-asserted-by":"publisher","first-page":"e66019","DOI":"10.1371\/journal.pone.0066019","volume":"8","author":"C Hoffmann","year":"2013","unstructured":"Hoffmann, C. et al. Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents. PLoS One 8, e66019 (2013).","journal-title":"PLoS One"},{"key":"961_CR187","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1017\/S0007114507793923","volume":"99","author":"A Costabile","year":"2008","unstructured":"Costabile, A. et al. Whole-grain wheat breakfast cereal has a prebiotic effect on the human gut microbiota: A double-blind, placebo-controlled, crossover study. Br. J. Nutr. 99, 110\u2013120 (2008).","journal-title":"Br. J. Nutr."},{"key":"961_CR188","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1017\/S0007114510002084","volume":"104","author":"AL Carvalho-Wells","year":"2010","unstructured":"Carvalho-Wells, A. L. et al. Determination of the in vivo prebiotic potential of a maize-based whole grain breakfast cereal: A human feeding study. Br. J. Nutr. 104, 1353\u20131356 (2010).","journal-title":"Br. J. Nutr."},{"key":"961_CR189","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1136\/gutjnl-2019-320008","volume":"69","author":"MC R\u00fchlemann","year":"2020","unstructured":"R\u00fchlemann, M. C. et al. Gut mycobiome of primary sclerosing cholangitis patients is characterised by an increase of Trichocladium griseum and Candida species. Gut 69, 1890\u20131892 (2020).","journal-title":"Gut"},{"key":"961_CR190","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1136\/gutjnl-2018-317791","volume":"69","author":"S Lemoinne","year":"2020","unstructured":"Lemoinne, S. et al. Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis. Gut 69, 92\u2013102 (2020).","journal-title":"Gut"}],"container-title":["npj Biofilms and Microbiomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41522-026-00961-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41522-026-00961-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41522-026-00961-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T11:03:05Z","timestamp":1777028585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41522-026-00961-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":190,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["961"],"URL":"https:\/\/doi.org\/10.1038\/s41522-026-00961-5","relation":{},"ISSN":["2055-5008"],"issn-type":[{"value":"2055-5008","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}